{"nctId":"NCT00437645","briefTitle":"Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension","startDateStruct":{"date":"2007-01"},"conditions":["Essential Hypertension"],"count":1183,"armGroups":[{"label":"Valsartan/amlodipine 160/5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Valsartan 160 mg capsules","Drug: Amlodipine 5 mg capsules","Drug: placebo"]},{"label":"Amlodipine 10 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Valsartan 160 mg capsules","Drug: Amlodipine 5 mg capsules","Drug: placebo"]}],"interventions":[{"name":"Valsartan 160 mg capsules","otherNames":[]},{"name":"Amlodipine 5 mg capsules","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female outpatients ≥ 55 years of age\n* Patients with essential hypertension measured using a validated automated oscillometric device at Visit 1\n* Non-treated patients must have a MSSBP ≥ 140 mmHg and ≤ 160 mmHg\n* Patients pre-treated on monotherapy prior to Visit 1 must have MSSBP ≤ 160 mmHg\n* To be eligible for randomization at Visit 2 (Day 1) all patients must have a MSSBP ≥ 130 mmHg and ≤ 160 mmHg\n* No peripheral edema at Visit 2 (randomization)\n* Written informed consent to participate in this study prior to any study procedures\n\nExclusion Criteria:\n\n* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant\n* Known or suspected contraindications, including history of allergy or hypersensitivity to angiotensin receptor blockers, calcium channel blockers, or to drugs with similar chemical structures\n* Patients taking more than 1 antihypertensive medication at Visit 1\n* Administration of any agent indicated for the treatment of hypertension after Visit 1 with the exception of pre-treated patients that require tapering down of anti-hypertensive treatments. For patients with previous antihypertensive medication that require a gradual downward titration, the tapering down should be done according to manufacturers instructions and last dose should be taken by week -2 prior to randomization\n* msSBP \\> 180 mmHg or msDBP \\> 110 mmHg at any time between Visit 1 and Visit 2\n* Evidence of a secondary form of hypertension, including but not limited to any of the following: Coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, polycystic kidney disease, or pheochromocytoma\n* History of hypertensive encephalopathy, cerebrovascular accident, transient ischemic attack, myocardial infarction, percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) 12 months prior to Visit 1\n* History of heart failure Grade II - IV according to the NYHA classification\n* Second or third degree heart block with or without a pacemaker\n* Concomitant potentially life threatening arrhythmia or symptomatic arrhythmia\n* Concomitant unstable angina pectoris\n* Clinically significant valvular heart disease\n* Patients with Type 1 diabetes mellitus\n* Patients with Type 2 diabetes mellitus who are not well controlled based on the investigator's judgment. It is recommended that Type 2 diabetic patients are adequately controlled and, if treated with medication, be on a stable dose of oral anti-diabetic medication for at least 4 weeks prior to Visit 1\n* Evidence of hepatic disease as determined by one of the following: AST or ALT values \\> 2x UNL at study entry, a history of hepatic encephalopathy, history of esophageal varices, or history of portocaval shunt\n* Evidence of renal impairment as determined by one of the following: serum creatinine \\> 1.5 x UNL at visit 1, history of dialysis, or history of nephrotic syndrome\n* Serum potassium values \\> 5.5 mmol/L at study entry\n* Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug\n* Any surgical or medical condition which, at the discretion of the investigator or Novartis medical monitor, places the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study period\n* Volume depletion based on the investigator's clinical judgment using vital signs, skin turgor, moistness of mucous membranes, and laboratory values\n* Any severe, life-threatening disease within the past five years\n* History of drug or alcohol abuse within the last 2 years\n* Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer\n* Inability to communicate and comply with all study requirements including the unwillingness or inability to provide informed consent\n* Persons directly involved in the execution of this protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"55 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 8","description":"Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \\< 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.01","spread":"0.5944"},{"groupId":"OG001","value":"-6.30","spread":"0.6088"}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients With Peripheral Edema From Baseline to Week 8","description":"Only occurrences of peripheral edema quantified as a reported adverse event coded as peripheral edema were included in the analysis. If a patient experienced more than one occurrence of peripheral edema between Day 1 and Week 8, it was only counted once in the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":null},{"groupId":"OG001","value":"31.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 8","description":"Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \\< 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.65","spread":"0.3616"},{"groupId":"OG001","value":"-4.13","spread":"0.3690"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Sitting Systolic and Diastolic Blood Pressure (msSBP, msDBP) From Baseline to Weeks 4, 8, and 12","description":"Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \\< 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.40","spread":"0.5559"},{"groupId":"OG001","value":"-6.48","spread":"0.5676"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.15","spread":"0.6065"},{"groupId":"OG001","value":"-6.11","spread":"0.6266"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.08","spread":"0.6968"},{"groupId":"OG001","value":"-7.82","spread":"0.7088"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.05","spread":"0.3559"},{"groupId":"OG001","value":"-4.23","spread":"0.3623"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.68","spread":"0.3632"},{"groupId":"OG001","value":"-3.97","spread":"0.3736"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.50","spread":"0.03735"},{"groupId":"OG001","value":"-4.90","spread":"0.3785"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving a Systolic Response at Weeks 4, 8, and 12","description":"Systolic response was defined as msSBP \\< 130 mmHg or at least a 20 mmHg reduction from baseline in msSBP at Weeks 4, 8, and 12. Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.07","spread":null},{"groupId":"OG001","value":"25.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.22","spread":null},{"groupId":"OG001","value":"25.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.96","spread":null},{"groupId":"OG001","value":"31.26","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":592},"commonTop":["Oedema peripheral","Headache"]}}}